Afinitor (Pancreatic cancer) – Analysis and Forecasts to 2020

Afinitor (Pancreatic cancer) – Analysis and Forecasts to 2020

Summary

GlobalData’s pharmaceuticals report, “Afinitor (Pancreatic cancer) - Analysis and Forecasts to 2020” provides Afinitor sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2011-2020). The report also includes information on Pancreatic Cancer market. This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.

Scope

- Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
- Analysis and review of Afinitor including sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Afinitor including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecasts from 2011-2020 for Afinitor in the seven major markets

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Introduction 4
2.1 Pancreatic Cancer 4
2.2 Pancreatic Cancer Market 4
2.3 Epidemiology 4
2.4 Etiology 6
2.4.1 Cigarette Smoking 6
2.4.2 Age 6
2.4.3 Gender 7
2.4.4 Family History 8
2.4.5 Other Factors 8
2.5 GlobalData Market Forecasts Report Guidance 9
3 Pancreatic Cancer: Market Characterization 10
3.1 Pancreatic Cancer Market 10
3.2 Pancreatic Cancer Market Forecasts and CAGR 10
3.3 Drivers for Pancreatic Cancer Market 11
3.3.1 High Prevalence 11
3.3.2 High Incidence 11
3.3.3 Large Unmet Need 12
4 Tumor-Node-Metastases (TNM) Classification of Pancreatic Cancer 13
5 Afinitor 16
5.1 Introduction 16
5.2 Mechanism of Action 16
5.3 Clinical Studies 16
5.3.1 Efficacy and Safety of everolimus (RAD001) in Patients with Advanced Neuroendocrine Tumors (RADIANT-3) 16
5.3.2 Safety/Efficacy of everolimus in Patients with Advanced Pancreatic Neuroendocrine Cancer not Responsive to Chemotherapy 16
5.4 Approval Status of Afinitor 17
5.5 Factors Affecting Sales of Afinitor 17
5.5.1 Lack of Competition in Japan 17
5.5.2 Higher Cost of Afinitor 17
5.5.3 Low Level of Competition 17
5.5.4 Pancreatic NETs is Uncommon 17
5.6 Drug Risk Benefit Score 17
5.6.1 Efficacy 18
5.6.2 Safety 18
5.6.3 Compliance 18
5.6.4 Dosing Convenience 18
5.7 Intensity of Competition 18
5.8 Sales Forecasts 18
5.8.1 Target Patient Pool of Afinitor 18
5.8.2 Dosing 19
5.8.3 Market Penetration 19
5.8.4 Annual Cost of Therapy 19
5.8.5 Sales Projections of Afinitor 20
6 Appendix 29
6.1 Market Definitions 29
6.2 List of Abbreviations 29
6.3 Research Methodology 29
6.3.1 Coverage 29
6.3.2 Secondary Research 29
6.3.3 Forecasting 30
6.3.4 Number of Patients Approved to take the Drug 30
6.3.5 Net Penetration of Drug 31
6.3.6 Net Annual Dosing 32
6.3.7 Annual Cost of Therapy 32
6.3.8 Primary Research 32
6.3.9 Expert Panels 32
6.4 Contact Us 32
6.5 Disclaimer 33
6.6 Sources 33